| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/19/2012 | WO2012007839A2 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract |
| 01/19/2012 | WO2012007728A2 Toxoiding method |
| 01/19/2012 | WO2012007688A1 Monoclonal antibodies to tetanus toxin |
| 01/19/2012 | WO2012007632A1 Use of edg2 inhibitors for treating rheumatoid arthritis |
| 01/19/2012 | WO2012007589A1 Live attenuated parvovirus |
| 01/19/2012 | WO2012007576A1 Superior efficacy of cd37 antibodies in cll blood samples |
| 01/19/2012 | WO2012007380A1 Modified viral strains, and method for improving the production of vaccine seeds of the influenza virus |
| 01/19/2012 | WO2012006962A1 Truncated human papillomavirus type 58 l1 protein |
| 01/19/2012 | WO2012006727A1 Human papillomavirus e7 antigen compositions and uses thereof |
| 01/19/2012 | WO2012006718A1 Carbohydrate hapten-based anti-cancer vaccines and antibody drugs |
| 01/19/2012 | WO2011153493A3 Biodegradable lipids for the delivery of active agents |
| 01/19/2012 | WO2011153243A3 Anti-angiogenesis therapy for treating gastric cancer |
| 01/19/2012 | WO2011143624A3 Humanized and chimeric monoclonal antibodies to cd47 |
| 01/19/2012 | WO2011116262A3 Compositions and methods for diagnosing and treating urinary tract infections |
| 01/19/2012 | WO2011112983A3 Psrp is a protective antigen against pneumococcal infection |
| 01/19/2012 | WO2011112915A3 Methods and compositions containing fc fusiong proteins for enhancing immune responses |
| 01/19/2012 | WO2011112873A3 Extracorporeal immunoadsorption treatment |
| 01/19/2012 | WO2011112859A3 Methods relating to olanzapine pharmacogenetics |
| 01/19/2012 | WO2011112850A3 Humanized and chimeric anti-properdin antibodies |
| 01/19/2012 | WO2011112549A3 Temperature sensitive conjugate compositions, and uses related thereto |
| 01/19/2012 | WO2011109494A3 A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin |
| 01/19/2012 | WO2011109398A3 Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| 01/19/2012 | WO2011109285A3 Prognostic marker for cryoglobulinemic vasculitis and b cell malignancies in hcv infected patients |
| 01/19/2012 | WO2011106376A3 Use of microvesicles in the treatment of medical conditions |
| 01/19/2012 | WO2011103426A3 Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof |
| 01/19/2012 | WO2011098762A3 Antibodies against cxcr4 |
| 01/19/2012 | WO2011091078A9 Antibody fc variants with enhanced complement activity |
| 01/19/2012 | WO2011034604A9 Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| 01/19/2012 | WO2010131733A9 Anti-axl antibody |
| 01/19/2012 | WO2009151503A3 Compositions and methods for the treatment of a neoplasia |
| 01/19/2012 | US20120016340 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 01/19/2012 | US20120015872 Complement receptor 2 targeted complement modulators |
| 01/19/2012 | US20120015871 Complement receptor 2 targeted complement modulators |
| 01/19/2012 | US20120015425 Cellular Permissivity Factor for Viruses and Uses Thereof |
| 01/19/2012 | US20120015402 Method of Proliferating Plasma Cells |
| 01/19/2012 | US20120015401 Plasmodium falciparum antigens and methods of use |
| 01/19/2012 | US20120015024 Methods for treating tweak-related conditions |
| 01/19/2012 | US20120015000 Malaria vaccine of self-assembling polypeptide nanoparticles |
| 01/19/2012 | US20120014998 Modified chaperonin 10 |
| 01/19/2012 | US20120014996 Method of diagnosing bladder cancer |
| 01/19/2012 | US20120014995 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents |
| 01/19/2012 | US20120014994 Malaria prime/boost vaccines |
| 01/19/2012 | US20120014993 Clostridium taeniosporum spores and spore appendages as surface display hosts, drug delivery devices, and nanobiotechnological structures |
| 01/19/2012 | US20120014992 N-Linked Glycosylation Alteration in E1 Glycoprotein of Classical Swine Fever Virus And Novel Classical Swine Fever Virus Vaccine |
| 01/19/2012 | US20120014991 Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces |
| 01/19/2012 | US20120014990 Vaccination methods |
| 01/19/2012 | US20120014988 Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements |
| 01/19/2012 | US20120014987 Dna vaccine for alzheimer's disease |
| 01/19/2012 | US20120014985 Vaccine Adjuvants |
| 01/19/2012 | US20120014984 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| 01/19/2012 | US20120014983 recombinant alpha-hemolysin polypeptide of staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| 01/19/2012 | US20120014982 Methods and Compositions for Immunizing Against Chlamydia Infection |
| 01/19/2012 | US20120014981 Avirulent, immunogenic flavivirus chimeras |
| 01/19/2012 | US20120014980 Vaccines comprising tb10.4 |
| 01/19/2012 | US20120014979 Use of bcl6 inhibitors for treating autoimmune diseases |
| 01/19/2012 | US20120014978 Compositions with reduced dimer formation |
| 01/19/2012 | US20120014977 NOVEL ALTERNATIVE SPLICING VARIANT OF OATP1B3 mRNA |
| 01/19/2012 | US20120014976 Compositions and methods for enhancing immune responses to vaccines |
| 01/19/2012 | US20120014974 Methods of modulating cell death based on the bit1/aes regulatory pathway |
| 01/19/2012 | US20120014973 Adenylyl cyclase-associated protein (cap1) and uses thereof as a target for immuno-modulation |
| 01/19/2012 | US20120014972 Influenza virus compositions and methods for universal vaccines |
| 01/19/2012 | US20120014971 Interleukin-1 Alpha Antibodies and Methods of Use |
| 01/19/2012 | US20120014970 Therapeutic Compositions for Treatment of Corneal Disorders |
| 01/19/2012 | US20120014969 ErbB3 ANTIBODIES |
| 01/19/2012 | US20120014968 Stabilized formulations containing anti-ngf antibodies |
| 01/19/2012 | US20120014967 Il-1beta binding antibodies and fragments thereof |
| 01/19/2012 | US20120014966 Methods for the treatment of il-1beta related conditions |
| 01/19/2012 | US20120014965 Compositions and methods of treating tumors |
| 01/19/2012 | US20120014964 Alpha synuclein toxicity |
| 01/19/2012 | US20120014963 Probiotics, secretory iga and infection |
| 01/19/2012 | US20120014962 Method of inhibiting fibrogenesis and treating fibrotic disease |
| 01/19/2012 | US20120014961 Antibodies that inhibit tslp activity |
| 01/19/2012 | US20120014960 Composition Comprising Antibodies to LINGO or Fragments Thereof |
| 01/19/2012 | US20120014959 Wise/sost nucleic acid sequences and amino acid sequences |
| 01/19/2012 | US20120014958 Stable and soluble antibodies inhibiting vegf |
| 01/19/2012 | US20120014957 Dual variable domain immunoglobulins and uses thereof |
| 01/19/2012 | US20120014956 Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor |
| 01/19/2012 | US20120014955 Antagonists of IL-6 to raise albumin and/or lower CRP |
| 01/19/2012 | US20120014954 Sparc binding scfvs |
| 01/19/2012 | US20120014953 Treating and evaluating inflammatory disorders |
| 01/19/2012 | US20120014952 Complement receptor 2 targeted complement modulators |
| 01/19/2012 | US20120014951 Pcsk9 antagonists |
| 01/19/2012 | US20120014950 Antibodies That Specifically Bind to DR3 |
| 01/19/2012 | US20120014949 Serum Biomarkers For Early Detection Of Acute Cellular Rejection |
| 01/19/2012 | US20120014948 Genetic products differentially expressed in tumors and use thereof |
| 01/19/2012 | US20120014947 Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system |
| 01/19/2012 | US20120014946 Prevention and treatment of pain using monoclonal antibodies and antibody fragments to lysophosphatidic acid |
| 01/19/2012 | US20120014945 Anti-Dengue Virus Antibodies |
| 01/19/2012 | US20120014944 Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| 01/19/2012 | US20120014943 Optimized Anti-CD30 Antibodies |
| 01/19/2012 | US20120014942 Method for the diagnosis and prognosis of malignant diseases |
| 01/19/2012 | US20120014941 Anti-bv8 antibodies and uses thereof |
| 01/19/2012 | US20120014940 Methods and compositions for diagnosis and treatment of malignant and non-malignant gammopathies |
| 01/19/2012 | US20120014918 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors |
| 01/19/2012 | US20120014916 Polyalkylene polymer compounds and uses thereof |
| 01/19/2012 | US20120014911 Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor |
| 01/19/2012 | US20120014874 Photosensitizer-metal nanoparticle charge complex and composition containing the complex for photodynamic therapy or diagnosis |
| 01/19/2012 | US20120014872 Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Various Cancers |
| 01/19/2012 | US20120014869 Muc18 targeting peptides |
| 01/19/2012 | CA2841866A1 Carbohydrate hapten-based anti-cancer vaccines and antibody drugs |